| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Stephens & Co. analyst Sudan Loganathan initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Overweight rating...
																	LifeSci Capital initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Outperform rating and announces Price Target o...
																	
																	$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company's financial position; ...
																	Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developi...
																	
																	HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ: CADL) with a Buy and maintains $...
																	CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to place...